Drug Profile
AZD 3161
Alternative Names: AZD3161Latest Information Update: 28 Apr 2016
Price :
$50
*
At a glance
- Originator AstraZeneca
- Class Analgesics
- Mechanism of Action Nav1.7 voltage-gated sodium channel inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Neuropathic pain; Pain
Most Recent Events
- 28 Apr 2016 Chemical structure information added
- 31 Dec 2010 Phase-I clinical trials in Neuropathic pain in United Kingdom (Intradermal)
- 31 Dec 2010 Phase-I clinical trials in Pain in United Kingdom (Intradermal)